Weekly analog of amylin, a pancreatic hormone that promotes satiety. Being investigated for weight loss, alone and combined with semaglutide (CagriSema).
Regulatory status
In clinical trials
Family
Long-acting amylin analog (amylin and calcitonin receptor agonist)
Scientific evidence
Moderate
Number of findings
1
Where it acts
Digestive and weight · Hormones and metabolism
Also known as
cagrilintide, NN9838, AM833
Regulatory status
FDA (US): Not approved (in phase 3, mainly as part of CagriSema).
EMA (EU): Not approved.
Dose
There is no established dose in humans. In the phase 2 trial, 0.3 to 4.5 mg subcutaneously once a week for 26 weeks was used (Lancet 2021).
Safety
Digestive effects (nausea, constipation, diarrhea) and injection-site reactions, more frequent than with placebo. Dropouts due to adverse effects of 2–6%. Use only in clinical trials or research, under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Weight loss in overweight or obesity
improvesModerateRCT (AA)in people
−10.8% weight
Phase 2 trial in 706 adults without diabetes, 26 weeks: weight loss was 6.0% to 10.8% depending on the dose, vs 3.0% with placebo. The 4.5 mg dose slightly outperformed liraglutide 3.0 mg (9.0%).
Mimics amylin, which is released together with insulin after eating. It acts in the brain to increase satiety and reduce intake, and it slows gastric emptying. Its effect is complementary to that of GLP-1 agonists.
What the evidence says
In people
Weight loss in overweight or obesity. Phase 2 trial in 706 adults without diabetes, 26 weeks: weight loss was 6.0% to 10.8% depending on the dose, vs 3.0% with placebo. The 4.5 mg dose slightly exceeded liraglutide 3.0 mg (9.0%). PubMed 34798060